Francis A Farraye
Francis A Farraye is an expert in Gastroenterology at Mayo Clinic (United States, Jacksonville) (United States). As of August 2026, ScienceLeadR ranks Francis A Farraye in the top 1% of experts worldwide for Inflammatory Bowel Diseases, Gastroenteritis and Colitis. Francis A Farraye has authored 789 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 1 of them ongoing. SLR score: 2,947 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Public Health - Pharmacy - Infectiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2002 - 2026
Number : 789
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Association Between Inflammatory Bowel Disease in Women and the Fertility Marker Anti-Müllerian Hormone. PMID 42629469 — sample size, fertility, hormones, inflammatory bowel diseases, anti-mullerian hormone, diagnosis, therapeutics | Dig Dis Sci | 2026 | 0 |
| Outcomes in adult liver transplant patients receiving recombinant herpes zoster vaccine. PMID 42322677 — liver transplantation, vaccines, liver, herpes zoster, diagnosis, transplants, herpes zoster vaccine | Vaccine | 2026 | 0 |
| Increased risk of respiratory syncytial virus infection in patients with active inflammatory bowel disease: a matched cohort study. PMID 42485230 — respiratory syncytial viruses, vaccines, crohn disease, pneumonia, bacterial, adrenal cortex hormones, cohort studies, vaccination, pneumonia, inflammatory bowel diseases, viruses, intensive care units, ventilation, colitis, ulcerative, infections, virus diseases, respiratory syncytial virus infections | Inflamm Bowel Dis | 2026 | 0 |
| Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis. PMID 42394415 — neoplasms, multiple chronic conditions, inflammatory bowel diseases, pharmacology, therapeutics, colorectal neoplasms, colitis, ulcerative | Aliment Pharmacol Ther | 2026 | 2 |
| Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study. PMID 42334197 — respiratory syncytial viruses, hospitalization, incidence, crohn disease, cohort studies, propensity score, inflammatory bowel diseases, veterans, viruses, therapeutics, intensive care units, colitis, ulcerative, infections, respiratory syncytial virus infections | Inflamm Bowel Dis | 2026 | 0 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Sustained Humoral and Cell Mediated Immunogenicity of COVID 19 Vaccines in Patients With Inflammatory Bowel Disease NCT05014555 — cells, vaccines, covid-19 vaccines, rna, messenger, covid-19, inflammatory bowel diseases, intestinal diseases | N/A | Not yet recruiting | 2023 |
LeadR Networks
Main global connection map